Medical Treatment of Aortic Stenosis
暂无分享,去创建一个
[1] P. F. Kauff. Group , 2000, Elegant Design.
[2] K. Toutouzas,et al. Inhibition of Aortic Valve Calcification by Local Delivery of Zoledronic Acid—an Experimental Study , 2018, Journal of Cardiovascular Translational Research.
[3] Y. Bossé,et al. Systolic hypertension and progression of aortic valve calcification in patients with aortic stenosis: results from the PROGRESSA study , 2017, European heart journal cardiovascular Imaging.
[4] Wing W. Chan,et al. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. , 2016, JAMA cardiology.
[5] Akshay S. Desai,et al. Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization. , 2016, Journal of the American College of Cardiology.
[6] J. Leipsic,et al. One-Year Clinical Outcomes With SAPIEN 3 Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Severe Aortic Stenosis , 2016, Circulation.
[7] M. Desai,et al. Association of Abnormal Postoperative Left Ventricular Global Longitudinal Strain With Outcomes in Severe Aortic Stenosis Following Aortic Valve Replacement. , 2016, JAMA cardiology.
[8] G. Thanassoulis. Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis , 2016, Journal of Lipid Research.
[9] Jeroen J. Bax,et al. Natural History, Diagnostic Approaches, and Therapeutic Strategies for Patients With Asymptomatic Severe Aortic Stenosis. , 2016, Journal of the American College of Cardiology.
[10] M. Mack,et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. , 2016, The New England journal of medicine.
[11] K. Yutzey,et al. Cardiac Fibrosis: The Fibroblast Awakens. , 2016, Circulation research.
[12] Akshay S. Desai,et al. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. , 2016, Circulation. Heart failure.
[13] J. Tardif,et al. Resting heart rate as a predictor of aortic valve stenosis progression. , 2016, International journal of cardiology.
[14] Cuihong Xie,et al. Angiotensin II promotes an osteoblast-like phenotype in porcine aortic valve myofibroblasts , 2016, Aging Clinical and Experimental Research.
[15] Y. Bossé,et al. Calcium Signaling Pathway Genes RUNX2 and CACNA1C Are Associated With Calcific Aortic Valve Disease , 2015, Circulation. Cardiovascular genetics.
[16] C. Macaya,et al. Incidence, Causes, and Predictors of Early (≤30 Days) and Late Unplanned Hospital Readmissions After Transcatheter Aortic Valve Replacement. , 2015, JACC. Cardiovascular interventions.
[17] G. Cioffi,et al. See Clinical Perspective See Editorial by Barasch and Reichek , 2022 .
[18] J. Witztum,et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study , 2015, The Lancet.
[19] Y. Bossé,et al. AUTOTAXIN ENHANCES AORTIC VALVE MINERALIZATION THROUGH A NF-κB / IL-6 / BMP-2 DEPENDENT INFLAMMATORY PATHWAY , 2015 .
[20] J. Tardif,et al. ALTERATIONS OF APOA-I/HDL TARGET RECEPTOR SR-BI AND LOX-1 IN PATIENTS WITH AORTIC VALVE STENOSIS , 2015 .
[21] J. Després,et al. SYSTOLIC HYPERTENSION AND PROGRESSION OF AORTIC VALVE CALCIFICATION IN PATIENTS WITH AORTIC STENOSIS - RESULTS FROM THE PROGRESSA STUDY , 2015 .
[22] J. Afilalo,et al. Complications Associated With Nitrate Use in Patients Presenting With Acute Pulmonary Edema and Concomitant Moderate or Severe Aortic Stenosis. , 2015, Annals of emergency medicine.
[23] Y. Bossé,et al. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calci fi c Aortic Valve Stenosis , 2017 .
[24] T. Akasaka,et al. Risk Factors for Progression of Degenerative Aortic Valve Disease in the Japanese- The Japanese Aortic Stenosis Study (JASS) Prospective Analysis. , 2015, Circulation journal : official journal of the Japanese Circulation Society.
[25] M. Dweck,et al. Calcification in Aortic Stenosis: The Skeleton Key. , 2015, Journal of the American College of Cardiology.
[26] Jiawei Shi,et al. Lazaroid U-74389G inhibits the osteoblastic differentiation of IL-1β-indcued aortic valve interstitial cells through glucocorticoid receptor and inhibition of NF-κB pathway , 2015, The Journal of Steroid Biochemistry and Molecular Biology.
[27] M. Mack,et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial , 2015, The Lancet.
[28] M. Mack,et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial , 2015, The Lancet.
[29] C. Held,et al. EACPR country of the month initiative: Sweden. , 2015, European heart journal.
[30] Yu Kataoka,et al. Impact of statins on serial coronary calcification during atheroma progression and regression. , 2015, Journal of the American College of Cardiology.
[31] Marie-Chloé Boulanger,et al. Adenosine derived from ecto-nucleotidases in calcific aortic valve disease promotes mineralization through A2a adenosine receptor. , 2015, Cardiovascular research.
[32] B. Prendergast,et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial) , 2015, European heart journal cardiovascular Imaging.
[33] P. Kovanen,et al. Is Blockade of the Renin-angiotensin System Able to Reverse the Structural and Functional Remodeling of the Left Ventricle in Severe Aortic Stenosis? , 2015, Journal of cardiovascular pharmacology.
[34] N. Weissman,et al. Hemodynamic outcomes of transcatheter aortic valve replacement and medical management in severe, inoperable aortic stenosis: a longitudinal echocardiographic study of cohort B of the PARTNER trial. , 2015, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[35] Y. Bossé,et al. Impact of plasma Lp-PLA2 activity on the progression of aortic stenosis: the PROGRESSA study. , 2015, JACC. Cardiovascular imaging.
[36] Vilmundur Gudnason,et al. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. , 2014, JAMA.
[37] M. Enriquez-Sarano,et al. Impact of aortic valve calcification, as measured by MDCT, on survival in patients with aortic stenosis: results of an international registry study. , 2014, Journal of the American College of Cardiology.
[38] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[39] L. Køber,et al. Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. , 2014, International journal of cardiology.
[40] Thoralf M Sundt,et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[41] Thoralf M Sundt,et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[42] M. Enriquez-Sarano,et al. Early regression of severe left ventricular hypertrophy after transcatheter aortic valve replacement is associated with decreased hospitalizations. , 2014, JACC. Cardiovascular interventions.
[43] Maurice Buchbinder,et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. , 2014, The New England journal of medicine.
[44] P. Barter,et al. Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). , 2014, The American journal of cardiology.
[45] C. Hassager,et al. Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in patients with severe aortic stenosis: a placebo-controlled, randomized study. , 2014, American heart journal.
[46] M. Sandhu,et al. Lipoprotein(a) levels, genotype and incident aortic stenosis: a prospective Mendelian randomization study and replication in a case-control cohort , 2013 .
[47] B. Nordestgaard,et al. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. , 2013, Journal of the American College of Cardiology.
[48] P. Pibarot,et al. The complex nature of discordant severe calcified aortic valve disease grading: new insights from combined Doppler echocardiographic and computed tomographic study. , 2013, Journal of the American College of Cardiology.
[49] P. Pibarot,et al. Impact of hypertension and renin–angiotensin system inhibitors in aortic stenosis , 2013, European journal of clinical investigation.
[50] J. Chambers,et al. Effect of overweight and obesity on cardiovascular events in asymptomatic aortic stenosis: a SEAS substudy (Simvastatin Ezetimibe in Aortic Stenosis). , 2013, Journal of the American College of Cardiology.
[51] R. Nishimura,et al. Systemic Hypertension in Low-Gradient Severe Aortic Stenosis With Preserved Ejection Fraction , 2013, Circulation.
[52] A. Bogers,et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. , 2013, Journal of the American College of Cardiology.
[53] F. Tubach,et al. Progression of aortic valve stenosis is associated with bone remodelling and secondary hyperparathyroidism in elderly patients--the COFRASA study. , 2013, European heart journal.
[54] B. Lutz,et al. Myocardial hypertrophy is associated with inflammation and activation of endocannabinoid system in patients with aortic valve stenosis. , 2013, Life sciences.
[55] P. Pellikka,et al. Prevention of atrial fibrillation in patients with aortic valve stenosis with candesartan treatment after aortic valve replacement. , 2013, International journal of cardiology.
[56] Ajit P. Yoganathan,et al. Aortic Valve: Mechanical Environment and Mechanobiology , 2013, Annals of Biomedical Engineering.
[57] A. Luttun,et al. Increased Cardiac Myocyte PDE5 Levels in Human and Murine Pressure Overload Hypertrophy Contribute to Adverse LV Remodeling , 2013, PloS one.
[58] Kathleen F. Kerr,et al. Genetic associations with valvular calcification and aortic stenosis. , 2013, The New England journal of medicine.
[59] R. Sacco,et al. Higher Ambulatory Blood Pressure Is Associated With Aortic Valve Calcification in the Elderly: A Population-Based Study , 2013, Hypertension.
[60] O. Alfieri,et al. Guidelines on the management of valvular heart disease (version 2012). , 2012, European heart journal.
[61] K. Masters,et al. A time course investigation of the statin paradox among valvular interstitial cell phenotypes. , 2012, American journal of physiology. Heart and circulatory physiology.
[62] J. Peteiro,et al. Association of Left Ventricular Mass with All-Cause Mortality, Myocardial Infarction and Stroke , 2012, PloS one.
[63] M. Dweck,et al. Osteoporosis is a major confounder in observational studies investigating bisphosphonate therapy in aortic stenosis. , 2012, Journal of the American College of Cardiology.
[64] P. Pibarot,et al. Inhibition of ectonucleotidase with ARL67156 prevents the development of calcific aortic valve disease in warfarin-treated rats. , 2012, European journal of pharmacology.
[65] J. Després,et al. Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy. , 2012, Journal of the American College of Cardiology.
[66] B. Gage,et al. Effects of Phosphodiesterase Type 5 Inhibition on Systemic and Pulmonary Hemodynamics and Ventricular Function in Patients With Severe Symptomatic Aortic Stenosis , 2012, Circulation.
[67] P. Garg,et al. 077 Osteoporosis and bisphosphonate's use associated with reduced progression of calcific aortic stenosis: retrospective observational single centre study , 2012, Heart.
[68] P. Heidenreich,et al. The effect of angiotensin-converting enzyme inhibitors and statins on the progression of aortic sclerosis and mortality. , 2012, The Journal of heart valve disease.
[69] A. Oto,et al. OP-281 ASSESSMENT OF THE RELATIONSHIP OF CHOLECALCIFEROL, CALCIUM CARBONATE AND ALENDRONATE TREATMENTS WITH AORTIC VALVE CALCIFICATION , 2012 .
[70] E. Tuzcu,et al. Do bisphosphonates slow the progression of aortic stenosis? , 2010, Journal of the American College of Cardiology.
[71] Y. Bossé,et al. Replication of genetic association studies in aortic stenosis in adults. , 2011, The American journal of cardiology.
[72] J. Després,et al. Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves , 2011, European journal of clinical investigation.
[73] K. Teo,et al. Lipid lowering on progression of mild to moderate aortic stenosis: meta-analysis of the randomized placebo-controlled clinical trials on 2344 patients. , 2011, The Canadian journal of cardiology.
[74] J. Pepper,et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. , 2011, Journal of the American College of Cardiology.
[75] P. Pellikka,et al. Noninvasive assessment of filling pressure and left atrial pressure overload in severe aortic valve stenosis: relation to ventricular remodeling and clinical outcome after aortic valve replacement. , 2011, The Journal of thoracic and cardiovascular surgery.
[76] C. Lang,et al. Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. , 2011, Journal of the American College of Cardiology.
[77] B. Mulder,et al. Effects of rosuvastatin on progression of stenosis in adult patients with congenital aortic stenosis (PROCAS Trial). , 2011, The American journal of cardiology.
[78] Stuart J Pocock,et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. , 2011, The New England journal of medicine.
[79] P. Willeit,et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. , 2011, Journal of the American College of Cardiology.
[80] Yuan Zhang,et al. Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations , 2011, British journal of pharmacology.
[81] A. Innasimuthu,et al. Effect of Bisphosphonates on the Progression of Degenerative Aortic Stenosis , 2011, Echocardiography.
[82] R. Arena,et al. PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study , 2011, Circulation. Heart failure.
[83] W. Keeling,et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery , 2011 .
[84] K. Linhartová,et al. Bisphosphonates in Calcific Aortic Stenosis: Association with Slower Progression in Mild Disease – A Pilot Retrospective Study , 2010, Cardiology.
[85] L. Schurgers,et al. Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis , 2010, Journal of internal medicine.
[86] S. Pocock,et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. , 2010, The New England journal of medicine.
[87] D. Koumoundourou,et al. Aldosterone receptor blockade inhibits degenerative processes in the early stage of calcific aortic stenosis. , 2010, European journal of pharmacology.
[88] P. Pellikka,et al. Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis. , 2010, The American journal of cardiology.
[89] Mario J. Garcia,et al. Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. , 2010, European heart journal.
[90] L. Schurgers,et al. The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. , 2010, Clinical journal of the American Society of Nephrology : CJASN.
[91] K. Teo,et al. Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial , 2010, Circulation.
[92] M. Cheitlin,et al. Hydroxymethylglutaryl Coenzyme-A Reductase Inhibitors Delay the Progression of Rheumatic Aortic Valve Stenosis: A Long-Term Echocardiographic Study , 2010 .
[93] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.
[94] W. Aronow,et al. Warfarin use and the risk of valvular calcification , 2009, Journal of thrombosis and haemostasis : JTH.
[95] P. Pibarot,et al. Usefulness of the valvuloarterial impedance to predict adverse outcome in asymptomatic aortic stenosis. , 2009, Journal of the American College of Cardiology.
[96] V. Persy,et al. Vascular calcification and bone disease: the calcification paradox. , 2009, Trends in molecular medicine.
[97] P. Kostenuik,et al. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice. , 2009, The American journal of pathology.
[98] I. Kronzon,et al. Osteoporosis treatment and progression of aortic stenosis. , 2009, The American journal of cardiology.
[99] S. Young,et al. Lowering Plasma Cholesterol Levels Halts Progression of Aortic Valve Disease in Mice , 2009, Circulation.
[100] A. Mahnken,et al. Relation of circulating matrix Gla-protein and anticoagulation status in patients with aortic valve calcification , 2009, Thrombosis and Haemostasis.
[101] M. Criqui,et al. Association of coronary artery and aortic calcium with lumbar bone density: the MESA Abdominal Aortic Calcium Study. , 2008, American journal of epidemiology.
[102] J. Chambers,et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.
[103] G. Feuchtner,et al. Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg). , 2008, The American journal of cardiology.
[104] H. White,et al. A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. , 2008, American heart journal.
[105] J. Després,et al. Association Between Plasma LDL Particle Size, Valvular Accumulation of Oxidized LDL, and Inflammation in Patients With Aortic Stenosis , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[106] G. Filippatos,et al. [Guidelines on the management of valvular heart disease]. , 2013, Revista espanola de cardiologia.
[107] J. Després,et al. Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis , 2007, Heart.
[108] J. Zamorano,et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. , 2007, Journal of the American College of Cardiology.
[109] N. Kostomitsopoulos,et al. The effects of enalapril on p53 expression in left ventricular cardiomyocytes after aortic stenosis. , 2006, In vivo.
[110] J. Després,et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. , 2006, Journal of the American College of Cardiology.
[111] T. Fleming,et al. Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.
[112] D. Srivastava,et al. Mutations in NOTCH1 cause aortic valve disease , 2005, Nature.
[113] S. Stock,et al. Atorvastatin Inhibits Hypercholesterolemia-Induced Calcification in the Aortic Valves via the Lrp5 Receptor Pathway , 2005, Circulation.
[114] Damien Garcia,et al. Reduced systemic arterial compliance impacts significantly on left ventricular afterload and function in aortic stenosis: implications for diagnosis and treatment. , 2005, Journal of the American College of Cardiology.
[115] D. Hardie,et al. Cannabinoids and Ghrelin Have Both Central and Peripheral Metabolic and Cardiac Effects via AMP-activated Protein Kinase* , 2005, Journal of Biological Chemistry.
[116] O. Florey,et al. Proinflammatory Activation of Macrophages by Basic Calcium Phosphate Crystals via Protein Kinase C and MAP Kinase Pathways: A Vicious Cycle of Inflammation and Arterial Calcification? , 2005, Circulation research.
[117] R. Prescott,et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. , 2005, The New England journal of medicine.
[118] W. Zapol,et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. , 2005, Chest.
[119] M. Budoff,et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. , 2005, Archives of internal medicine.
[120] B. Popescu,et al. Progression of aortic valve sclerosis and aortic valve stenosis: what is the role of statin treatment? , 2005, Italian heart journal : official journal of the Italian Federation of Cardiology.
[121] D. Kass,et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.
[122] M. Mäyränpää,et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. , 2004, Journal of the American College of Cardiology.
[123] M. Schemper,et al. Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis , 2004, Circulation.
[124] M. Enriquez-Sarano,et al. Evaluation and Clinical Implications of Aortic Valve Calcification Measured by Electron-Beam Computed Tomography , 2004, Circulation.
[125] P. Ridker. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. , 2004, American heart journal.
[126] R Alagesan,et al. Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). , 2004, American heart journal.
[127] A. Urtti,et al. Effect of Liposomal and Free Bisphosphonates on the IL-1β, IL-6 and TNFα Secretion from RAW 264 Cells in Vitro , 1995, Pharmaceutical Research.
[128] B. Popescu,et al. Effect of statins on the progression of bioprosthetic aortic valve degeneration. , 2003, The American journal of cardiology.
[129] K. Fox,et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.
[130] Karl Swedberg,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.
[131] M. Pfeffer,et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.
[132] Philippe Ravaud,et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. , 2003, European heart journal.
[133] D. Lamontagne,et al. Endocannabinoids protect the rat isolated heart against ischaemia , 2003, British journal of pharmacology.
[134] J. Goding,et al. Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family. , 2003, Biochimica et biophysica acta.
[135] E. Tuzcu,et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. , 2003, The New England journal of medicine.
[136] M. Enriquez-Sarano,et al. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. , 2002, Journal of the American College of Cardiology.
[137] P. Vandervoort,et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. , 2002, Journal of the American College of Cardiology.
[138] R. Bonow,et al. Atorvastatin Inhibits Hypercholesterolemia-Induced Cellular Proliferation and Bone Matrix Production in the Rabbit Aortic Valve , 2002, Circulation.
[139] J. Cohn,et al. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.
[140] G. Ertl,et al. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. , 2001, Journal of the American College of Cardiology.
[141] M. Lauer,et al. Effect of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors on the Progression of Calcific Aortic Stenosis , 2001, Circulation.
[142] W. Aronow,et al. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. , 2001, The American journal of cardiology.
[143] P. Price,et al. Bisphosphonates Alendronate and Ibandronate Inhibit Artery Calcification at Doses Comparable to Those That Inhibit Bone Resorption , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[144] F. Ohme,et al. Lack of association among five genetic polymorphisms of the renin-angiotensin system and cardiac hypertrophy in patients with aortic stenosis. , 2001, American heart journal.
[145] E Fleck,et al. Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. , 2001, Journal of the American College of Cardiology.
[146] R. Choudhury,et al. New insights into the progression of aortic stenosis: implications for secondary prevention. , 2000, Circulation.
[147] B. Pitt,et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .
[148] R. Pai,et al. New insights into the progression of aortic stenosis: implications for secondary prevention. , 2000, Circulation.
[149] S. Adami,et al. Chronic Intravenous Aminobisphosphonate Therapy Increases High‐Density Lipoprotein Cholesterol and Decreases Low‐Density Lipoprotein Cholesterol , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[150] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[151] M. Eriksson,et al. Angiotensin-converting enzyme gene polymorphism influences degree of left ventricular hypertrophy and its regression in patients undergoing operation for aortic stenosis. , 1999, The American journal of cardiology.
[152] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[153] P. Libby,et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[154] P. Kaufmann,et al. Effect of NO donors on LV diastolic function in patients with severe pressure-overload hypertrophy. , 1999, Circulation.
[155] J. Thyberg,et al. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[156] R. Alexander,et al. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. , 1998, Circulation research.
[157] H. Schunkert,et al. Regulation of extracellular matrix proteins in pressure‐overload cardiac hypertrophy: effects of angiotensin converting enzyme inhibition , 1998, Journal of hypertension.
[158] R. Behringer,et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein , 1997, Nature.
[159] Catherine M. Otto,et al. Clinical Factors Associated With Calcific Aortic Valve Disease , 1997 .
[160] Bonnie K. Lind,et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. , 1997, Journal of the American College of Cardiology.
[161] S. Yusuf,et al. Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .
[162] S. Yusuf,et al. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. , 1995, JAMA.
[163] A. Urtti,et al. Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. , 1995, Pharmaceutical research.
[164] W. Aronow,et al. Prognosis of congestive heart failure in patients aged > or = 62 years with unoperated severe valvular aortic stenosis. , 1993, The American journal of cardiology.
[165] H. Ikram,et al. Hemodynamic effects of nitroprusside on valvular aortic stenosis. , 1992, The American journal of cardiology.
[166] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[167] F. Tristani,et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.
[168] M. Webb-Peploe,et al. Echocardiographic left ventricular wall thickness: A poor predictor of the severity of aortic valve stenosis , 1991, Clinical cardiology.
[169] S. Davies,et al. Progression of valvar aortic stenosis: a long-term retrospective study. , 1991, European heart journal.
[170] K. Misono,et al. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. , 1990, The Journal of biological chemistry.
[171] D E Manyari,et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.
[172] K. Swedberg,et al. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.
[173] Franz Schwarz,et al. The Effect of Aortic Valve Replacement on Survival , 1982, Circulation.
[174] S. Rahimtoola,et al. Severe Aortic Stenosis in Patients 60 Years of Age and Older: Left Ventricular Function and 10‐year Survival After Valve Replacement , 1981, Circulation.
[175] R. Miller,et al. Beneficial effects of nitroprusside administration on left ventricular dysfunction and myocardial ischemia in severe aortic stenosis. , 1981, American heart journal.
[176] R. Miller,et al. Effects of isometric exercise and increased arterial impedance on left ventricular function in severe aortic valvular stenosis. , 1977, British heart journal.